Answers are grounded in this paper and cite their sources.
Background Metabolic and renal outcomes with semaglutide added to dapagliflozin in routine clinical practice remain incompletely characterized. Objective To compare metabolic and renal outcomes between dapagliflozin monotherapy and dapagliflozin plus semaglutide in a real-world Saudi cohort using a balanced composite endpoint. Methods Retrospective observational cohort of 295 patients initiated on dapagliflozin ± once-weekly semaglutide at King Abdulaziz Hospital, MNGHA, Al-Ahsa (follow-up 90–360 days). The primary outcome was a balanced response, defined as ≥5% BMI reduction without ≥10% eGFR decline. Primary analyses used IPTW-weighted Poisson and linear regression models. A prespecified standalone multivariable linear regression was performed separately to evaluate the HbA1c finding, with rigorous adjustment for baseline glycemic status. Results Among 295 patients (189 dapagliflozin-only; 106 dapagliflozin plus semaglutide), the balanced response occurred in 13.2% versus 16.0% (IPTW-adjusted RR 1.37; 95% CI 0.79–2.38). BMI response was numerically higher with semaglutide add-on (17.5% vs 24.5%; RR 1.49, 95% CI 0.95–2.33). Renal safety was similar across groups. The IPTW-adjusted HbA1c difference favored dapagliflozin alone (+0.51%; 95% CI, 0.07–0.96); a standalone multivariable regression confirmed that this reflects a baseline HbA1c imbalance and regression to the mean rather than reduced semaglutide efficacy. Conclusions Semaglutide add-on was associated with a numerically greater BMI response and balanced metabolic and renal benefits, with no evidence of renal harm. The HbA1c finding is attributable to baseline imbalance and should not be interpreted as reduced glycemic efficacy. Larger prospective studies with standardized dose assessment are needed.
No takes yet. Share an insight, caveat, or question.
AlTaweel et al. (2026) studied this question.